View in EDS HTML Full Text PDF Full Text

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM.

Saved in:
Bibliographic Details
Title: Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM.
Authors: Huemer, Florian1, Melchardt, Thomas1, Jansko, Bettina1, Wahida, Adam2, Jilg, Stefanie2, Jost, Philipp J.2, Klieser, Eckhard3, Steiger, Katja4, Magnes, Teresa1, Pleyer, Lisa1, Greil‐Ressler, Sigrun1, Rass, Christof1, Greil, Richard1, Egle, Alexander1 a.egle@salk.at
Source: European Journal of Haematology. May2019, Vol. 102 Issue 5, p437-441. 5p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:09024441
DOI:10.1111/ejh.13218